Cann Pharmaceutical Australia (CPA) has a large number of proprietary strains that are 100% pesticide-free and manufactured into proven phytocannabinoid medical-grade drugs and treatments for specific conditions. All of CPA's strains conform to Therapeutic Goods (Standard for Medicinal Cannabis (TGO 93) Order 2017.
Conditions targeted by CPA's products include: Chronic pain, neuropathic pain, epilepsy and PTSD, among others.
CPA has formulated a collection of THC and CBD ratios, available for both sublingual administration and inhalation. Depending on patient needs, CBD-rich or THC-rich ratios may be selected from.
For more information about these products, healthcare professionals should register to CPA's medical portal - which serves as an information hub for doctors, clinicians and other medical professionals in considering commencing prescription of medicinal cannabis for patients. Registration can be found in the bottom right corner of the menu bar.